Clinical Trial Search

Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52

Primary: Depression From (1) Clinician-Administered MADRS Measure, and (2) Participant Self-Report Ratings With BDI-1a — 17.8; 19.2; 19.7; 17.7 Units on a scale

Primary: Adherence Measured by Sensor by Percentage of Prescribed Medications Taken — 87.5 percentage of prescribed medication

Primary: Medication Adherence as Assessed by the Medication Event Monitoring System (MEMS) Cap — 52.2; 27.2 percentage of participants

Primary: Change in Tenofovir Diphosphate (TFV-DP) Drug Levels — 1230; 1108; 1887; 1084 fmol/punch — p=0.070

Primary: Mean Adherence, as Measured by Electronic Drug Monitors (EDM) — 96.5; 84.5; 96.4; 84.1 percentage of doses taken on time

Primary: Rate of Medication Adherence — 2; 1 Participants

Primary: Number of Participants ≥90% Adherent to Antiretroviral Medication Based on MEMS Cap Openings — 9; 5 Participants — p=0.32

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus - Type I Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 50 Copies/mL at Week 12 — 24.4; 20.9…

Primary: Proportion of Participants in Each Arm Achieving Viral Suppression to <50 Copies/ml — 59; 48 Participants

Primary: Number of Participants Who Reported Experiences With the ARICA Program — 12 Participants

Primary: Antiretroviral Therapy (ART) Adherence (Self-reported 3-day Recall Measure) — 142; 139; 6; 12 participants

Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12

Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants

Primary: Proportion of Pills Taken as Prescribed Over the Intervention Period (Baseline - Month 3) — 0.860; 0.916; 0.914 Proportion of pills taken as prescribed — p=0.056

Primary: Feasibility: Rate of Participant Retention — 22 Participants

Primary: Medication Adherence — 77.96; 80.13; 64.87; 76.13 Percentage of doses taken — p=.005

Primary: Adherence to Anti-Retroviral Therapy (ART) at the End of 12-Week Intervention Period — 91.07; 96.00; 99.82; 94.81 percentage of times pills taken

Primary: Overall MEMS Adherence to Antiretroviral Medication — 68.0; 70.4 percentage of taken doses — p=0.68

Primary: Adherence to Statins — 0.55; 0.57; 0.58; 0.38 mMPR as a fraction — p=<.001

Primary: Self-reported Adherence to Artemisinin-combination Therapy (ACT) Treatment — 61.5; 69.0; 64.1 percentage of participants

Primary: Intervention Feasibility as Measured by Number of Providers Agreeing to Participate — 6 Participants

Primary: Proportion Adherent to ARV and Psychotropic Medication by Electronic Monitoring System (MEMS) — 90.3; 90.0; 83.9; 90.0 percentage of taken doses — p=0.95

Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78

Primary: Confirmed Virologic Failure at or Prior to Week 48 — 95; 105; 34; 23 participants — p=0.133

Primary: Self-Reported ART Adherence — 56.67; 58.7 Percentage of successful doses

Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103

Primary: Change in Antiretroviral Therapy (ART) Adherence Rates — 27.04; 26.25; 26.14; 26.48 score on a scale

Primary: ART Adherence at 20 Weeks as Determined by VAS, Viral Load — 57; 47; 63; 46 Participants

Primary: TFV-diphosphate (TFV-DP) Drug Level — 1377.82; 1156.79 fentomole/punch — p=.014